273 related articles for article (PubMed ID: 31292127)
21. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.
Lexchin J; Batt S; Goldberg D; Shnier A
BMJ Open; 2022 Mar; 12(3):e055287. PubMed ID: 35264357
[TBL] [Abstract][Full Text] [Related]
22. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
23. Interactions between physicians and the pharmaceutical industry: what does the literature say?
Lexchin J
CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
[TBL] [Abstract][Full Text] [Related]
24. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
25. Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey.
Rathi VK; Strait KM; Gross CP; Hrynaszkiewicz I; Joffe S; Krumholz HM; Dzara K; Ross JS
Trials; 2014 Oct; 15():384. PubMed ID: 25277128
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
27. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study.
Varma T; Mello M; Ross JS; Gross C; Miller J
BMJ Med; 2023; 2(1):e000395. PubMed ID: 36936269
[TBL] [Abstract][Full Text] [Related]
28. Institutional dashboards on clinical trial transparency for University Medical Centers: A case study.
Franzen DL; Carlisle BG; Salholz-Hillel M; Riedel N; Strech D
PLoS Med; 2023 Mar; 20(3):e1004175. PubMed ID: 36943836
[TBL] [Abstract][Full Text] [Related]
29. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
30. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
31. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
32. EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets - a primer for academic researchers.
Sudlow R; Branson J; Friede T; Morgan D; Whately-Smith C
BMC Med Res Methodol; 2016 Jul; 16 Suppl 1(Suppl 1):73. PubMed ID: 27410386
[TBL] [Abstract][Full Text] [Related]
33. Transparency and objectivity in governance of clinical trials data sharing: Current practices and approaches.
Shabani M; Obasa M
Clin Trials; 2019 Oct; 16(5):547-551. PubMed ID: 31347399
[TBL] [Abstract][Full Text] [Related]
34. Benchmarking the nutrition-related commitments and practices of major French food companies.
Van Dam I; Vandevijvere S
BMC Public Health; 2022 Jul; 22(1):1435. PubMed ID: 35902838
[TBL] [Abstract][Full Text] [Related]
35. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.
Zwierzyna M; Davies M; Hingorani AD; Hunter J
BMJ; 2018 Jun; 361():k2130. PubMed ID: 29875212
[TBL] [Abstract][Full Text] [Related]
37. Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation.
Fortunato A; Grainger DW; Abou-El-Enein M
Adv Drug Deliv Rev; 2018; 136-137():97-104. PubMed ID: 29408180
[TBL] [Abstract][Full Text] [Related]
38. Company stock prices before and after public announcements related to oncology drugs.
Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
[TBL] [Abstract][Full Text] [Related]
39. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
Kato M; Ishikawa H; Okuhara T; Kiuchi T
Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
